Literature DB >> 10590002

Two-year follow-up of laser in situ keratomileusis for hyperopia.

S Esquenazi1, A Mendoza.   

Abstract

PURPOSE: To evaluate excimer laser in situ keratomileusis (LASIK) for hyperopia and its predictability.
METHODS: We performed a retrospective study of 100 eyes that had LASIK for hyperopia to assess predictability and long-term stability of refractive results. The Chiron Automated Corneal Shaper was used to create the flap and the Keracor 117CT Chiron-Technolas excimer laser with the plano-scan program was used to ablate all corneas.
RESULTS: Mean baseline spherical equivalent manifest refraction was +4.50 +/- 1.73 D (range, +1.25 to +8.50 D). Six months after LASIK, mean manifest spherical equivalent refraction was +0.72 +/- 1.87 D (range, -1.75 to +2.50 D), at 1 year, +0.88 +/- 1.73 D (range, -1.25 to +2.50 D), and at 2 years, +0.85 +/- 1.74 D (range, -0.50 to +2.75 D). Two years after LASIK, 45 eyes (74%) were within +/-1.00 D of intended correction and within +/-1.00 D of emmetropia. Uncorrected visual acuity was 20/40 or better in 50 eyes (82%) at 2 years; 29 eyes (37%) saw 20/20 or better. Undercorrection occurred more frequently in eyes with preoperative keratometric power of more than 45.00 D, when ablation zones less than 6 mm were used and when higher amounts of hyperopic correction were required.
CONCLUSION: LASIK with the Keracor 117CT excimer laser appears to be an effective and safe procedure to correct hyperopia. Preoperative keratometric power, amount of hyperopia, and ablation zone diameter affect the efficacy and long-term stability of the procedure.

Entities:  

Mesh:

Year:  1999        PMID: 10590002     DOI: 10.3928/1081-597X-19991101-08

Source DB:  PubMed          Journal:  J Refract Surg        ISSN: 1081-597X            Impact factor:   3.573


  12 in total

1.  Conductive keratoplasty for the correction of hyperopia.

Authors:  P A Asbell; R K Maloney; J Davidorf; P Hersh; M McDonald; E Manche
Journal:  Trans Am Ophthalmol Soc       Date:  2001

2.  Comparison of clinical outcome of small-incision lenticule intrastromal keratoplasty and FS-LASIK for correction of moderate and high hyperopia.

Authors:  Li Zhang; Yue-Hua Zhou; Chang-Bin Zhai; Jing Zhang; Yan Zheng
Journal:  Int J Ophthalmol       Date:  2022-05-18       Impact factor: 1.645

3.  Intraoperative flap complications in laser in situ keratomileusis with two types of microkeratomes.

Authors:  Hani S Al-Mezaine; Saleh A Al-Amro; Saleh Al-Obeidan
Journal:  Saudi J Ophthalmol       Date:  2011-04-23

4.  [Corneal wound healing after hyperopic PRK and LASIK].

Authors:  T Hammer; S Giessler; G I W Duncker; E Peschke
Journal:  Ophthalmologe       Date:  2005-01       Impact factor: 1.059

5.  Analysis of the keratocyte apoptosis, keratocyte proliferation, and myofibroblast transformation responses after photorefractive keratectomy and laser in situ keratomileusis.

Authors:  Steven E Wilson
Journal:  Trans Am Ophthalmol Soc       Date:  2002

6.  The effect of preoperative keratometry on visual outcomes after moderate myopic LASIK.

Authors:  Steven M Christiansen; Marcus C Neuffer; Shameema Sikder; Rodmehr T Semnani; Majid Moshirfar
Journal:  Clin Ophthalmol       Date:  2012-03-21

7.  Outcomes of Retreatment after Aborted Laser In Situ Keratomileusis due to Flap Complications.

Authors:  Hani S Al-Mezaine; Saleh A Al-Amro; Abdulaziz Al-Fadda; Saleh Al-Obeidan
Journal:  Middle East Afr J Ophthalmol       Date:  2011-07

8.  Anti-Apoptotic Gene Delivery with cyclo-(d-Trp-Tyr) Peptide Nanotube via Eye Drop Following Corneal Epithelial Debridement.

Authors:  Yu-Hsing Lee; Shwu-Fen Chang; Jiahorng Liaw
Journal:  Pharmaceutics       Date:  2015-07-17       Impact factor: 6.321

9.  Long-Term Followup of Laser In Situ Keratomileusis for Hyperopia Using a 213 nm Wavelength Solid-State Laser.

Authors:  Carmina Franz G Quito; Archimedes Lee D Agahan; Raymond P Evangelista
Journal:  ISRN Ophthalmol       Date:  2013-03-03

10.  One Year Outcomes of Photorefractive Keratectomy with the Application of Mitomycin-C in the Treatment of Mild to Moderate Hyperopia.

Authors:  Alireza Habibollahi; Hassan Hashemi; Mohammad Amin Seyedian; Shiva Mehravaran; Soheila Asgari; Sam Habibollahi; Sina Habibollahi; Mehdi Khabazkhoob
Journal:  Middle East Afr J Ophthalmol       Date:  2015 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.